Literature DB >> 29476829

Management of red blood cell alloimmunization in pregnancy.

L Ghesquière1, C Garabedian2, C Coulon2, P Verpillat3, T Rakza4, B Wibaut5, A Delsalle6, D Subtil2, P Vaast2, V Debarge2.   

Abstract

The main cause of fetal anemia is maternal red blood cell alloimmunization (AI). The search of maternal antibodies by indirect antiglobulin test allows screening for AI during pregnancy. In case of AI, fetal genotyping (for Rh-D, Rh-c, Rh-E and Kell), quantification (for anti-rhesus antibodies) and antibody titration, as well as ultrasound monitoring, are performed. This surveillance aims at screening for severe anemia before hydrops fetalis occurs. Management of severe anemia is based on intrauterine transfusion (IUT) or labor induction depending on gestational age. After intrauterine transfusion, follow-up will focus on detecting recurrence of anemia and detecting fetal brain injury. With IUT, survival of fetuses with alloimmunization is greater than 90% but 4.8% of children with at least one IUT have neurodevelopmental impairment.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Alloimmunization; Fetal anemia; Hydrops; Intrauterine transfusion; Ultrasound

Mesh:

Year:  2018        PMID: 29476829     DOI: 10.1016/j.jogoh.2018.02.001

Source DB:  PubMed          Journal:  J Gynecol Obstet Hum Reprod        ISSN: 2468-7847


  2 in total

1.  ABO and Rh Antigen Distribution Among Pregnant Women in South Western Uganda.

Authors:  Yona Mbalibulha; Bernard Natukunda; Okwi Andrew Livex; Sam Ononge; Joan N Kalyango; Isaac Kajja
Journal:  J Blood Med       Date:  2022-06-22

2.  Quantitative comparative analysis of human erythrocyte surface proteins between individuals from two genetically distinct populations.

Authors:  Benjamin J Ravenhill; Usheer Kanjee; Ambroise Ahouidi; Luis Nobre; James Williamson; Jonathan M Goldberg; Robin Antrobus; Tandakha Dieye; Manoj T Duraisingh; Michael P Weekes
Journal:  Commun Biol       Date:  2019-09-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.